<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8090">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01722604</url>
  </required_header>
  <id_info>
    <org_study_id>CD-11-265</org_study_id>
    <nct_id>NCT01722604</nct_id>
  </id_info>
  <brief_title>Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnoPharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnoPharma Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this prospective study is to demonstrate the therapeutic equivalence of
      topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic
      suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Intraocular pressure (IOP) at baseline (Eligibility Visit 2) weeks and after treatment.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in intraocular pressure (IOP) from baseline (Eligibility Visit 2) and after treatment.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">258</enrollment>
  <condition>Glaucoma,</condition>
  <condition>Open Angle or Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Azopt 1% ophthalmic suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ophthalmic suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brinzolamide 1% ophthalmic suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ophthalmic suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brinzolamide 1% ophthalmic suspension</intervention_name>
    <description>brinzolamide 1% ophthalmic suspension</description>
    <arm_group_label>Brinzolamide 1% ophthalmic suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azopt 1%</intervention_name>
    <description>Azopt 1%, RLD</description>
    <arm_group_label>Azopt 1% ophthalmic suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females 18 years of age or older,

          -  diagnosed with primary open-angle glaucoma or ocular hypertension.

        Exclusion Criteria:

          -  Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal
             tension glaucoma, angle closure glaucoma) in either eye other than primary open-angle
             glaucoma,

          -  ocular hypertension.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Various</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 6, 2012</lastchanged_date>
  <firstreceived_date>November 5, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
